IL28B polymorphism and early anemia predict the rapid null response in genotype-1 chronic hepatitis C with dual therapy  by Teng, Wei et al.
Advances in Digestive Medicine (2015) 2, 128e134Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.aidm-onl ine.comORIGINAL ARTICLEIL28B polymorphism and early anemia
predict the rapid null response in
genotype-1 chronic hepatitis C with
dual therapy
Wei Teng a, Tzu-Ching Chang b, Chien-Hao Huang b,
Wen-Juei Jeng b, Wei-Ting Chen b, Chang-Wen Huang b,
Yu-Pin Ho a, Chun-Yen Lin b,c,*, I-Shyan Sheen b,c,*a Department of Gastroenterology and Hepatology, Linkou Medical Center, Chang Gung Memorial
Hospital, Taoyuan, Taiwan
b Division of Hepatology, Department of Gastroenterology and Hepatology, Linkou Medical Center,
Chang Gung Memorial Hospital, Taoyuan, Taiwan
c School of Medicine, College of Medicine, Chang Gung University, Taoyuan, TaiwanReceived 14 February 2014; accepted 24 June 2014










creapolymorphismorresponding authors. Division of
cal Center, Number 5, Fu-Hsin St
-mail addresses: chunyenlin@gma
//dx.doi.org/10.1016/j.aidm.201
-9797/Copyright ª 2015, The Gas
he Study of the Liver. Published
tivecommons.org/licenses/by-nc-Summary Background and aims: Rapid null response (rNR), defined as less than one log
decline of Hepatitis C virus (HCV-RNA) at Week 4 of treatment with pegylated interferon-a
and ribavirin (PegIFN/RBV), is highly correlated with treatment failure in patients with chronic
hepatitis C (CHC), genotype-1 (GT-1). In this study, we investigate the possible predictors of
rNR.
Methods: We retrospectively analyzed a cohort of 199 GT-1 CHC naive patients who had been
treated with a dual therapy of PegIFN/RBV. Clinical parameters and genotypes of rs12979860,
the single nucleotide polymorphisms (SNPs) of interleukin-28B (IL28B) were analyzed for their
relationship with rNR.
Results: Of the patients analyzed, 41.7% did not exhibit a rapid virological response (RVR).
Only 13.1% of patients who experienced a rNR showed an RVR. The treatment failure rate
was 36.2%. High baseline viral load (OR: 5.74; p Z 0.028), nonrapid virological response
(non-RVR; OR: 4.32; p Z 0.004) and rNR (OR: 51.82; p < 0.001) were the predictors of treat-
ment failure. In addition, both the non-CC allele of rs12979860 (OR: 13.8; p < 0.001) and the
Hb (hemoglobin) decline to < 3 g/dL within 4 weeks of treatment (no early anemia; OR: 4.6;
p Z 0.024) were predictors of rNR.Hepatology, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou
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Predictors of rNR in GT-1 CHC 129Conclusions: rNR predicted treatment failure early in GT-1 CHC patients treated with PegIFN/
RBV. Non-CC genotype of rs12979860 and no early anemia were significant predictors of rNR.
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The development of direct-acting antiviral agents (DAAs)
for the treatment of chronic hepatitis C (CHC) has revolu-
tionized the treatment strategies [1,2]. Although DAAs are
now incorporated into the standard of care in Western
countries [1], dual therapy of pegylated interferon-a
and ribavirin (PegIFN/RBV) is still a popular and effective
treatment in countries where DAAs are not available or not
affordable [3e5]. The goals of treatment for CHC are to
eradicate the hepatitis C virus (achieving sustained viral
response, SVR) and to decrease the risks of cirrhosis, he-
patocellular carcinoma, and hepatic decompensation [6,7].
According to previous studies, PegIFN/RBV could achieve
42e79% of the SVR rate in HCV genotype 1 (GT-1) [4,8].
However, almost all patients treated with PegIFN/RBV
experienced one or more adverse events during the course
of therapy. Adverse reactions are a major reason that pa-
tients decline or stop therapy altogether. In the registration
trials of peginterferon-a-2a and 2b plus RBV, 10e14% of
patients had to discontinue therapy due to an adverse
event. Moreover, these undesirable side effects may in-
crease morbidity [8]. Therefore, predictors of treatment
failure, to avoid unnecessary treatment and treatment-
related side effects, are as important as predictors of
successful treatment.
The new reagents (DAAs) have been introduced into the
treatment protocol to reduce the treatment failure rate
and to rescue the patients who were failed by PegIFN/RBV
[2]. Therefore, the factors contributing to treatment
failure with dual therapy in GT-1 patients became an
interesting and important issue to explore. No early viro-
logical response (EVR; null response) or positivity of HCV-
RNA at Week 24 of treatment is the stopping rule. Less
than one log HCV-RNA decay at Week 4 has been reported
to predict treatment failure accurately and is the single
strongest predictor for treatment failure [9]. Therefore,
rapid null response (rNR) was named. However, in the
triple therapy of PegIFN/RBV/boceprevir or telaprevir,
viral response at Week 4 after a lead-in phase can also
predict treatment outcomes [1,10]. This highlights the
role of rNR not only in dual therapy, but also in the era of
triple therapy.
In addition, interleukin-28B (IL28B) single nucleotide
polymorphisms (SNPs) rs12979860 are powerful predictors
for SVR [11e14]. Lindh et al. [15] reported that IL28B SNPs
influence the early viral kinetics in GT-1 CHC patients
treated with PegIFN/RBV. Therefore, we conducted this
study to clarify the relationship between rNR and treat-
ment failure, and the association between IL28B SNP and
rNR.Patients and methods
Patients
We retrospectively analyzed a cohort of treatment naive
GT-1 CHC patients who had been treated with a combina-
tion therapy of PegIFN/RBV at Chang Gung Memorial Hos-
pital, Linkou Medical center and agreed to receive genomic
study of IL28B between June 2007 and May 2011. All had
received liver biopsies that were evaluated using the Met-
avir and Ishak scoring system. Patients with other
concomitant liver diseases, such as hepatitis B virus, human
immunodeficiency virus, alcoholic liver disease, and auto-
immune hepatitis, were excluded. PegIFN/RBV included
either peginterferon-a-2a (180 mg/week) or peginterferon-
a-2b (1.5 mg/kg/week) subcutaneously plus weight-based
ribavirin (1000 mg/day for weight < 75 kg and 1200 mg/
day for weight > 75 kg). Patients who did not fulfill the 80/
80/80 adherence rule were also not enrolled. A total of 213
GT-1 CHC patients were identified. Fourteen were excluded
because of no viral data at Week 4 or Week 12 in nine pa-
tients and no hemoglobin (Hb) data before Week 4 in five
patients. Baseline characters of these 14 patients were
comparable with those of the total cohort. There were 199
patients remaining in the study.
Definitions of treatment responses by serum level of
HCV-RNA were: undetectable HCV-RNA 24 weeks after the
cessation of treatment as sustained virological response
(SVR), undetectable HCV-RNA at Week 4 of treatment as
rapid virological response (RVR), and at least two log
reduction of HCV-RNA from baseline at treatment Week 12
as EVR. The rNR was defined as less than one log decline of
HCV-RNA at treatment Week 4. Those who failed to achieve
SVR were defined as treatment failures. Patients who did
not achieve EVR and therefore terminated PegIFN/RBV
early were also counted as treatment failures.
Because of changing reimbursement policies by the Bu-
reau of National Health Insurance according to professor
Yu’s study [16]. For analytical convenience, patients were
divided into two groups according to treatment duration.
The standard treatment regimen included a 48-week
treatment for patients with no RVR, patients with RVR but
high baseline viral load (HCV-RNA > 0.4  106 IU/ml), and a
24-week treatment for patients with RVR and low baseline
viral load (HCV-RNA < 0.4  106 IU/ml). Another group
received a shortened treatment regimen which was a 24-
week treatment for both patients with no RVR and pa-
tients with RVR but with high baseline viral load. No EVR
was applied as the stop rule to both standard and shortened
treatment regimens. Treatment was terminated if HCV-RNA
was detectable at 24 weeks. During the treatment, early
130 W. Teng et al.anemia was defined as a decline of Hb more than 3 g/dL
before or at Week 4.
The HCV-RNA levels in this study were measured using a
commercial quantitative polymerase chain reaction (PCR)
assay, either VERSANT HCV RNA 3.0. Assay (HCV 3.0 bDNA
assay, Bayer Diagnostics, Berkeley, CA, USA, lower limit of
detection: 5.2  102 IU/mL) or COBAS TaqMan HCV Test
(TaqMan HCV; Roche Molecular Systems Inc., Branchburg,
NJ, USA, lower limit of detection: 15 IU/mL). If non-
detection of HCV-RNA using the VERSANT HCV RNA 3.0 assay
occurred, it would be tested further using the COBAS
AMPLICOR HCV test, v2.0 (CA V2.0, Roche Diagnostic Sys-
tems, Pleasanton, CA, USA, lower limit of detection: 50 IU/
mL). The HCV genotype was determined using a genotype-
specific probe-based assay in the 50 untranslated region
(LiPA; Innogenetics, Ghent, Belgium).
Genomic DNA extraction and IL28 B genotyping
Anticoagulated peripheral blood was obtained from HCV
patients. Genomic DNA was isolated from EDTA anti-
coagulated peripheral blood using the Puregene DNA
isolation kit (Gentra Systems, Minneapolis, MN, USA) as
previously described [12]. The oligonucleotide sequences
flanking 10 IL28B polymorphisms were designed as primers
for Taqman allelic discrimination. The allele specific
primers for rs12979860 were labeled with a fluorescent dye
(FAM and VIC) and used in the PCR reaction. Aliquots of the
PCR product were genotyped with allele specific probes of
SNPs using real-time PCR (ABI).
Ethics statements
All patients in this study provided written informed con-






Male, n (%) 114 (57.3) 35 (48.
Age, y, mean (SD) 54.0 (11.2) 56.9 (10.
Necroinflammatory score,
medium (range)
5 (1e13) 5 (1e1
Cirrhosis, n (%) 50 (25.1) 26 (36.
BMI, kg/m2, mean (SD) 24.5 (3.4) 24.7 (2.9
Baseline HCV RNA > 0.4mIU/mL, n (%) 158 (79.4) 66 (91.
Baseline HCV RNA, log IU/mL, mean (SD) 6.2 (0.9) 6.4 (0.6
ALT, IU/L, mean (SD) 113 (81) 102 (68)
g-GT, IU/L, mean (SD) 76.3 (85.7) 81 (81)
rs12979860 of CT þ TT, n (%) 42 (21.1) 29 (40.
Baseline Hb, g/dL, mean (SD) 14.5 (1.6) 14.2 (1.6
Hb decline < 3g/dL at Week 4, n (%) 130 (65.3) 51 (70.
rNR, n (%) 26 (13.1) 26 (36.
No RVR, n (%) 116 (58.3) 62 (86.
Treatment failure, n (%)
ALT Z alanine transaminase; BMI Z body mass index; cirrhosis Z I
transpeptidase; Hb Z hemoglobin; necroinflammatory score Z I
RBV Z pegylated interferon-a and ribavirin; rNR Z rapid null responguidelines of the 1975 Declaration of Helsinki and was
approved by the ethical committees of Chang Gung Me-
morial Hospital.
Statistical analysis
The Chi-square test was used to compare the categorical
variables of the groups. Continuous variables were
compared using the Student t test or Mann-Whitney U test.
Logistic regression analyses for predictors of treatment
failure and rNR were conducted using patients’ de-
mographics, clinical variables, and IL28B SNPs. The clinical
variables included gender, age, viral load of HCV-RNA,
stage of fibrosis, body mass index (BMI), alanine trans-
aminase (ALT), g-glutamyl transpeptidase (g-GT), Hb, and
rs12979860 SNPs. The odds ratios (OR) and 95% confidence
intervals (95% CI) were also calculated. All p values < 0.05
by the two-tailed test were considered statistically signifi-
cant. Variables that achieved a statistical significance <
0.05 on univariate analysis were entered into multivariate
logistic regression analysis to identify the significant inde-
pendent predictive factors. All statistical analyses were
performed with statistical software, SPSS for Windows
(version 16, SPSS. Inc., Chicago, IL, USA) and SAS version 9.2
software (The SAS Institute, Cary, NC, USA).
Results
rNR had significant impact on treatment failure
The demographic characteristics of the 199 GT-1-CHC pa-
tients are shown in Table 1. Their mean age was 54.0  11.2
years and 57.3% (n Z 114) were male. Forty-two (21.1%)
patients had the CT or TT allele of IL28B. Standardis C patients treated with PegIFN/RBV.







6) 79 (62.2) 0.062 15 (57.7) 99 (57.2) 0.964
0) 52.3 (11.5) 0.011 54.0 (9.4) 53.9 (11.5) 0.890
0) 5 (1e13) 0.639 6 (2e9) 5 (1e13) 0.803
1) 24 (18.9) 0.007 8 (30.8) 42 (24.3) 0.477
) 24.4 (3.6) 0.450 25.2 (3.0) 24.4 (3.4) 0.215
7) 92 (72.4) 0.001 22 (84.6) 136 (78.6) 0.480
) 6.1 (1.0) 0.340 5.8 (0.6) 6.2 (0.9) 0.414
120 (87) 0.090 94 (51) 116 (85) 0.390
74 (92) 0.128 96.2 (55.8) 73.2 (89.2) 0.004
3) 13 (10.2) < 0.001 18 (69.2) 24 (13.9) < 0.001
) 14.7 (1.5) 0.028 14.4 (1.7) 14.5 (1.6) 0.867
8) 79 (62.2) 0.219 23 (88.5) 107 (61.8) 0.003
1) 0 (0) < 0.001
1) 54 (42.5) < 0.001 26 (100) 90 (52.0) < 0.001
26 (100) 46 (26.6) < 0.001
shak fibrosis stages 5e6 or Metavir F4; g-GT Z gamma-glutamyl
shak modified HAI (histological activity index) score; PegIFN/
se; RVR Z rapid virological response.
Predictors of rNR in GT-1 CHC 131treatment was received by 119 (59.8%) patients and 80
(40.2%) patients had shortened treatment. Sixty-nine
(34.7%) patients developed early anemia. There were 116
(58.3%) patients who could not reach RVR and 26 (13.1%)
patients demonstrated a rNR. The treatment failure rate in
these patients was 36.1% (nZ 72). The factors of older age,
cirrhosis, baseline Hb level, high baseline viral load, CT/TT
allele of rs12979860, no RVR and rNR were significantly
associated with treatment failure (Table 1). Multivariate
logistic regression revealed high baseline viral load (OR:
5.74; p Z 0.028), non-RVR (OR: 4.32; p Z 0.004) and rNR
(OR: 51.82; p < 0.001) were the independent significant
predictors of treatment failure (Table 2).
Both IL28B polymorphism and no early anemia
predict the rNR
The current analysis highlights the importance of rNR in
predicting treatment failure due to high OR. Differences
between patients who demonstrated rNR and those who did
not were examined. As shown in Table 1, patients demon-
strating rNR had higher levels of GGT (96.2  55.8 IU/L vs.
73.2 89.2 IU/L, pZ 0.004), were more likely to display the
nonfavorable alleles (CT/TT) of rs12979860 (69.2% vs. 13.9%,
p < 0.001), and were less likely to have early anemia (88.5%
vs.61.8%, pZ 0.003). Therefore, the possible predictors for
rNR were analyzed. As shown in Table 2, by multivariate
logistic analysis, only the CT/TT allele of rs12979860 (OR:
13.8, p < 0.001) and no early anemia (OR: 4.6, p Z 0.024)
were predictors of rNR. The factors associated with early
anemia including gender, age, cirrhosis, baseline Hb level,
BMI and rNR, as shown in Table 3, were also analyzed. Age
(OR: 1.04, pZ 0.004) and rNR (OR: 5.56, pZ 0.007) were the
two factors associated with early anemia. An age of  55
years with AUROC (Area Under Receiver Operating Charac-
teristic) of 0.62 (pZ 0.004, 95% CI: 0.54e0.71) was found to
increase the likelihood of early anemia.
Patient groups were divided according to the genotype
of rs12979860 and their treatment responses analyzed
separately. As shown in Fig. 1, significantly higher rates of
rNR (40.5% vs. 5.7%, p < 0.001), non-EVR (38.1% vs. 7.0%,
p < 0.001), non-RVR (88.1% vs. 50.3%, p < 0.001), nonend of














CI Z confidence interval; Hb Z hemoglobin; OR Z odds ratio; rNR Zp < 0.001), relapse rate (17.6% vs. 15.1%, p < 0.001) and
treatment failure (69.0% vs. 27.4%, p < 0.001) were
observed in patients with the CT/TT allele than in those
with the CC allele. In addition, because no early anemia
also had significant impact on the rNR, this effect was
analyzed in patients with different genotypes of
rs12979860. In patients with the CC allele, those with no
early anemia were significantly more likely to demonstrate
rNR than patients with early anemia (100% vs. 0%,
p Z 0.027, Table 4). No such correlation was observed in
patients with the CT/TT allele (83.3% vs. 16.7%, pZ 0.299,
Table 4).Discussion
This study strongly supports the notion that rNR is a
powerful predictor of treatment failure in patients with GT-
1 CHC receiving PegIFN/RBV. CT/TT genotypes of
rs12979860 and Hb decline  3 g/dL by Week 4 (no early
anemia) were the only two predictors of rNR.
Previous studies have shown that rNR has a high positive
predictive value for treatment failure [9,16]. Reau et al. [9]
reported that 24% of all patients treated with PegIFN/RBV
demonstrated rNR and 92% of patients could not achieve
SVR. In addition, Yu et al. [16] reported that a poor Week 4
response, defined as a reduction of HCV RNA reduction of
less than one log IU/mL or HCV RNA > 10,000 IU/mL (in non-
TT genotype), has a high negative predictive value (95%) for
treatment response. In this study, all patients demon-
strating an rNR (13.1%) failed to achieve sustained viral
response to the PegIFN/RBV regimen. These results support
the proposal to use the simple viral kinetic measurement,
rNR, to identify patients unlikely to have an early SVR
during treatment.
Single nucleotide polymorphism of IL28B has been
acknowledged as an important host predictor for SVR in
patients with GT-1 CHC treated with PegIFN/RBV
[11e14,17]. In this study, rs12979860 is not only a predictor
for SVR, but also a predictor for rNR. In another large
Taiwanese cohort study, Huang et al. [18] showed that host
IL-28B polymorphisms play a determinant role in patients
with moderate viral reduction at Week 4. Hsu et al. [19]ent responses and rNR.








L 5.7 1.2e57.0 0.028
1
4.3 1.5e13.9 0.004
rapid null response; RVR Z rapid virological response.
Table 3 Factors associated with early anemia.
Variables Univariate Multivariable
OR 95% CI p OR 95% CI p
Gender Male 1
Female 1.095 0.61e1.96 0.760
Age 1.040 1.01e1.07 0.006 1.042 1.01e1.07 0.006
Cirrhosis Yes 1
No 1.139 0.59e2.20 0.697
Baseline Hb 1.196 0.99e1.44 0.061
BMI 1.015 0.93e1.11 0.737
rNR Yes 1 1
No 5.46 1.59e20.0 0.007 5.65 1.59e20.0 0.007
BMI Z body mass index; CI Z confidence interval; Hb Z hemoglobin; OR Z odds ratio; rNR Z rapid null response.
Figure 1 The correlation between treatment responses and rs12979860. non-EOTVR Z non-end of treatment virological
response; non-EVR Z non-early virological response; non-RVR Z non-rapid virological response; rNR Z rapid null response.
Table 4 The influence of no early anemia on rNR in patients with RS12979860.
Rs12979860
Early CC allele Non-CC allele
Anemia rNR p rNR p
Yes (n Z 8) No (n Z 149) Yes (n Z 18) No (n Z 24)
Yes, n (%) 0 (0) 58 (38.9) 0.027 3 (16.7) 8 (33.3) 0.299
No, n (%) 8 (100) 91 (61.1) 15 (83.3) 16 (66.7)
rNR Z rapid null response.
132 W. Teng et al.constructed a unique hepatitis C viral kinetic model and
showed that different SNPs in IL28B have different thera-
peutic responses. Lindh et al. [15] reported that the IL28B
SNP of rs12979860 has significant influence on early viral
kinetics. The extent of decrease of HCV RNA level at Week 4
of treatment of patients with the CC allele of rs12979860
treated with PegIFN/RBV is higher than those in patients
with the CT or TT allele of rs12979860. This study shows
that patients with the CT/TT allele of rs12979860 demon-
strate a higher proportion of rNR, non-EVR, non-RVR, non-
EOTVR, relapse rate and treatment failure. These results
again emphasize the significant impact of genotype of IL28B
on the viral kinetics after PegIFN/RBV treatment.Treatment related anemia has long been a significant
adverse event. Compliance of 80/80/80 has been the
golden rule of treatment. In 2010, Sulkowski et al. [20]
reported that anemia resulting from chronic hepatitis C
treatment with PegINF/RBV was associated with a higher
SVR rate. Subsequently, several reports also demonstrated
that a higher SVR rate was evident in patients who had
treatment-related anemia. Sievert et al. [21] found that
anemia (Hb < 10 g/dL) and a significant decline of Hb (>
3 g/dL) during Weeks 5e48 of treatment are associated
with a higher rate of SVR. In another retrospective study,
both early anemia with hemoglobin < 11.5 g/dL within 4
weeks of treatment and hemoglobin decline > 3 g/dL were
Predictors of rNR in GT-1 CHC 133associated with higher rates of SVR [22]. Based on these
studies, the relationship between SVR and the timing and
extent of hemoglobin decline is still controversial. In this
study, hemoglobin decline of & 3 g/dL before Week 4 was
not a significant predictor for treatment failure (pZ 0.219)
but was a significant predictor for rNR (p Z 0.008). Two
associated factors with early anemia were old age (S 55
years) and rNR. Therefore, the relationship between early
Hb decline and rNR was further analyzed in different IL28B
SNPs. In patients with the CC allele of rs12979860, Hb
decline of & 3g/dL within 4 weeks of treatment was a
significant (PZ 0.027) predictor for rNR but similar analysis
was not significant (P Z 0.299) in patients with a non-CC
allele of rs12979860. Due to the small case number in the
non-CC allele group further studies with larger populations
are required to validate these findings.
The reason why anemia is related to treatment
response is still unclear but the theory of individual
pharmacokinetic response to ribavirin is supported by the
study findings. According to previous studies, ribavirin
reaches a steady state of serum concentration after 3e12
weeks of continued dosing and the drug is well known for
its hemolytic effect [21e23]. Therefore, no early anemia
after treatment possibly represents low serum concen-
tration of ribavirin and may be associated with rNR. It is
also reported that inosine triphosphate pyrophosphatase
(ITPA) polymorphism plays a role in ribavirin induced
anemia [24]. It would be interesting to examine the
relationship between ITPA polymorphisms, rNR, and early
anemia. However, ITPA polymorphisms were beyond the
scope of this study and therefore are not included in this
discussion.
In the new era of using DAAs to treat GT-1 CHC patients,
rNR should also be considered when developing a treatment
strategy. Based on SPRINT-2 and RESPOND-2 studies, less
than one log of viral load decline after a 4-week lead-in
treatment is strongly associated with failure of SVR in GT-1
CHC patients who received boceprevir/PegIFN/RBV treat-
ment [10,25,26]. Current practice guidelines suggest that
treatment with telapravir/PegIFN/RBV should be stopped if
the HCV RNA level is > 1000 IU/mL at treatment Week 4
[27]. Therefore, early viral kinetics still play an important
role in the era of DAAs. Although the viral load decline of
less than one log after a 4-week lead-in treatment is
associated with a relatively poor response of triple therapy
with boceprevir/PegIFN/RBV, combination treatment con-
taining DAAs still leads to SVR in about one third of the
patients who respond poorly to interferon. According to the
Phase III trial of boceprevir (SPRINT-2), the addition of
boceprevir significantly improved SVR rates from 4% with a
conventional treatment regimen to 28e38% with a boce-
previr containing treatment regimen [25,26]. Thus, current
guidelines suggest that a poor response during the lead-in
phase should not preclude patients from using boceprevir
[27]. Even though DAAs should be made available to this
group of patients, it is important to consider the treatment
timing. As most patients with rNR cannot attain SVR either
with or without boceprevir, especially patients with the
non-CC allele of IL28B SNP, it may be advisable to defer
treatment with DAAs until more potent forms are devel-
oped. This becomes particularly relevant when the side
effects and cost of DAAs and the potential for HCV resistantvariants that may jeopardize treatment response of future
regimens are considered.
In conclusion, rNR has high negative predictive value for
sustained virologic response as confirmed by this study and
previous reports. The genotype of CT/TT alleles of
rs12979860 are important predictors for rNR. In addition,
Hb decline of & 3 g/dL is also a predictor of rNR in GT-1
CHC patients treated with a combination regimen of
PegIFN/RBV. The findings from this study highlighted both
genotype of IL28B and early anemia had significant impact
on the rNR that in turn lead to the treatment failure.
In summary, this study clearly demonstrates that both
the genotype of rs12979860 and no early anemia are pre-
dictors for rNR.Conflicts of interest
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